This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Qingjun Wei
Guangxi Medical University First Affiliated Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-0570-4085
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background. Ewing sarcoma (EWS) is the second most familiar bone or soft-tissue sarcoma, making the identification of EWS biomarkers critically important. This study aimed to explore and validate potential prognostic biomarkers in EWS by bioinformatics analysis and experiments.
Methods The microarray dataset GSE119546 was downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) between EWS cells treated with and without Cyclin-dependent kinase 9 (CDK9) inhibitors were analyzed using R package limma. Next, we performed gene enrichment analysis and constructed a protein-protein interaction (PPI) network. The expression level of the top18 hub genes and the overall survival (OS) in patients with sarcoma were validated using the Oncomine and Gene Expression Profiling Interactive Analysis 2 (GEPIA2) databases. Furthermore, the mRNA expression of Bystin Like (BYSL), Nucleolar Protein 11 (NOL11), and P21-activated protein kinase-interacting protein 1 (PAK1IP1) was detected by RT-PCR in the EWS cell line (A-673), and the protein expression in EWS tissue was verified by immunohistochemistry (IHC).
Results Our study identified 343 DEGs, which were associated with various cancer-related functions and pathways. A total of three DEGs, including BYSL, NOL11, and PAK1IP1, were identified as hub genes with prognostic values using GEPAI2 and Oncomine. Finally, RT-PCR results showed the mRNA expression level of BYSL, NOL11, and PAK1IP1 in A-673 cells was higher than that in human mesenchymal stem cells. IHC staining revealed a positive expression ratio of NOL11, BYSL, and PAK1IP1 was 63.6% (14/22), 31.9% (7/22), and 0% (0/22), respectively. Cox regression analysis confirmed NOL11 was a significant prognostic factor for OS.
Conclusions. Our findings revealed that NOL11 may be a potential biomarker for EWS prognosis and treatment.
Keywords
Ewing sarcoma, bioinformatics analysis, prognosis, biomarker, NOL11
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 01 Feb, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Qingjun Wei
Guangxi Medical University First Affiliated Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-0570-4085
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 01 Feb, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background. Ewing sarcoma (EWS) is the second most familiar bone or soft-tissue sarcoma, making the identification of EWS biomarkers critically important. This study aimed to explore and validate potential prognostic biomarkers in EWS by bioinformatics analysis and experiments.
Methods The microarray dataset GSE119546 was downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) between EWS cells treated with and without Cyclin-dependent kinase 9 (CDK9) inhibitors were analyzed using R package limma. Next, we performed gene enrichment analysis and constructed a protein-protein interaction (PPI) network. The expression level of the top18 hub genes and the overall survival (OS) in patients with sarcoma were validated using the Oncomine and Gene Expression Profiling Interactive Analysis 2 (GEPIA2) databases. Furthermore, the mRNA expression of Bystin Like (BYSL), Nucleolar Protein 11 (NOL11), and P21-activated protein kinase-interacting protein 1 (PAK1IP1) was detected by RT-PCR in the EWS cell line (A-673), and the protein expression in EWS tissue was verified by immunohistochemistry (IHC).
Results Our study identified 343 DEGs, which were associated with various cancer-related functions and pathways. A total of three DEGs, including BYSL, NOL11, and PAK1IP1, were identified as hub genes with prognostic values using GEPAI2 and Oncomine. Finally, RT-PCR results showed the mRNA expression level of BYSL, NOL11, and PAK1IP1 in A-673 cells was higher than that in human mesenchymal stem cells. IHC staining revealed a positive expression ratio of NOL11, BYSL, and PAK1IP1 was 63.6% (14/22), 31.9% (7/22), and 0% (0/22), respectively. Cox regression analysis confirmed NOL11 was a significant prognostic factor for OS.
Conclusions. Our findings revealed that NOL11 may be a potential biomarker for EWS prognosis and treatment.
Figure 1
Figure 2
Figure 3
Loading...